Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a......
(read more)
May 23 - Hedge Funds - Comments
Biotechs with market caps of a billion dollars or more are a dime a dozen. Well, actually, they’re more like $12 billion or more a dozen, but you......
(read more)
April 23 - News - Comments
They’re demanding. They take risks — but only calculated ones. And they ask lots of penetrating questions to understand as much as possible......
(read more)
April 22 - News - Comments
There’s never a shortage of losers in the stock market. Let’s take a closer look at five of this past week’s biggest sinkers. Company......
(read more)
April 21 - News - Comments
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......
(read more)
April 20 - News - Comments
ImmunoGen, Inc. (NASDAQ:IMGN) investors should pay attention to a decrease in hedge fund interest recently. At the moment, there are dozens of methods......
(read more)
April 19 - News - Comments
A lot has been written this week — at The Fool and elsewhere — about Sarepta Therapeutics Inc (NASDAQ:SRPT)‘ update on its meeting......
(read more)
April 18 - News - Comments
So much for the big correction. Although the Dow Jones Industrial Average didn’t completely regain all the ground it lost the day before, the 157......
(read more)
April 17 - News - Comments
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case......
(read more)
April 16 - News - Comments
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced yesterday after the market closed that the U.S. Food and Drug Administration requested additional information......
(read more)
April 16 - News - Comments
There is always something interesting happening in the Bio-Pharma sector due to a number of firms working on several new drugs. Sarepta Therapeutics Inc......
(read more)
April 16 - News - Comments
The Dow Jones Industrial Average (Dow Jones Indices:.DJI) flashed a 60-point gain yesterday driven higher by the tech sector and its old dynamic duo,......
(read more)
April 10 - News - Comments
You can find investment ideas in the strangest places. Take Obamacare, for example. The legislation runs more than 900 pages long and is chock-full of......
(read more)
April 5 - News - Comments
They don’t have any products on the market. They have little or no revenue. Earnings? Nada. Many people are betting that they will fail. And yet......
(read more)
April 4 - News - Comments
With the Nasdaq Biotechnology Index hitting record highs, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat......
(read more)
March 22 - News - Comments
When building your portfolio, aim for diversification. You should aim to hold both large and small companies (plus mid-sized ones) and companies in a......
(read more)
March 20 - News - Comments
As first-quarter earnings begin to wind down, I can’t help but point out that the majority of earnings reports we’ve covered over the past......
(read more)
March 11 - News - Comments
Sarepta Therapeutics Inc (NASDAQ:SRPT) was on fire in 2012, landing at the top of the list of The Motley Fool’s best health-care stocks of the year......
(read more)
March 7 - News - Comments
With no PDUFA decisions on the plate this week, we’ll instead turn our attention to two important FDA panel meetings and two earnings reports that......
(read more)
March 4 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a......
(read more)
February 20 - Hedge Funds - Comments
How many of us as investors want to identify companies that are pioneers in their industry? Is it possible to find commonality across sectors, which factors......
(read more)
February 18 - News - Comments
